Effectiveness, Safety and Pharmacokinetics of BGM0504 , a Dual GLP ‐1/ GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial
Authors' conclusion
Once-weekly BGM0504 was associated with substantial dose-dependent weight loss and acceptable tolerability in Chinese adults with overweight or obesity without diabetes
Study context
- Population
- Chinese adults with overweight or obesity without diabetesassigned 1:1:1:1
- Participants
- 120 adults
- Comparison
- Once-weekly SC BGM0504 5 mg, 10 mg or 15 mg vs placebo
- Primary endpoint
- Percentage change in body weight from baseline
- Follow-up
- Week 24
Methodological detailsphase 2, multicentre, double-blind, placebo-controlled, parallel-group
- Phase 2
- Multicentre
- Double-blind
- Placebo-controlled
- Parallel-group
Primary result
As reported in the abstract
Mean % change in body weight · baseline to week 24
BGM0504 5 mg
−10.68%
mean
BGM0504 10 mg
−16.07%
mean
BGM0504 15 mg
−18.33%
mean
Placebo
0.13%
mean
All p < 0.0001
Secondary outcomes
Mean, cm
| Outcome | BGM0504 5 mg | BGM0504 10 mg | BGM0504 15 mg | Placebo | P value |
|---|---|---|---|---|---|
| Mean reduction in waist circumferenceBGM0504 5 mg, 10 mg, 15 mg vs Placebo | −8.88 | −12.71 | −14.38 | −1.03 | all p < 0.001 vs. placebo |
- Clinically meaningful weight loss · BGM0504 5 mg, 10 mg, 15 mg vs Placebo
- all p < 0.001
Clinically meaningful weight loss
- Proportions achieving clinically meaningful weight loss increased dose-dependently across BGM0504 groups vs placebo
Pharmacokinetics
- Approximately linear dose-exposure relationship across the evaluated dose range
Safety
TEAEs
Drug-related adverse events
Other safety results
- Serious adverse event in the 10 mg group
- One
- Most common selected TEAEs were gastrointestinal (nausea, diarrhoea, vomiting)
- No TEAEs led to trial withdrawal
Original publication
Effectiveness, Safety and Pharmacokinetics of BGM0504 , a Dual GLP ‐1/ GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial. Diabetes Obes Metab. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →